NCI Applied Research Program Technical Services

The National Institutes of Health, National Cancer Institute established this Master IDIQ on September 12, 2014 to procure technical services supporting methodological research, survey data collection tools, clinical databases, and analysis of cancer control data — but ordering closed on September 11, 2021, and the vehicle is no longer available for new task orders.

The vehicle is inactive and fully obligated. Five task orders were placed over a two-year span (2014–2016), totaling $497 thousand in combined potential value, with all funds obligated. The most recent order was issued September 7, 2016. No new work can be awarded under this vehicle.

The single substantial order was a $491 thousand delivery to The CDM Group Inc. for technical evaluation of the Cancer Control P.L.A.N.E.T. website platform (September 2016–September 2018, Cost Plus Fixed Fee). The remaining four orders, placed in September 2014, were small-dollar firm-fixed-price contracts under $2.5 thousand each for business overview and introduction webinars, distributed among Vignet Inc., Gunnison Consulting Group Inc., and Vsolvit LLC.

The CDM Group Inc. captured nearly all activity, holding two orders worth $492 thousand (99% of combined potential value). Competition was minimal — four prime contractors shared five orders across the vehicle's life. The entire ordering history served a single customer: the National Cancer Institute. Eighty percent of orders carried a Total Small Business set-aside; one order (the largest, to The CDM Group Inc.) was unrestricted.

This vehicle is closed to new business development. It may retain historical value for understanding NCI's technical services procurement patterns or for tracking previous performance with the customer, but no pursuit opportunity exists.

The National Cancer Institute, Division of Cancer Control and Population Sciences (DCCPS), Applied Research Programs (ARP) is seeking technical support of methodological research to improve survey data collection and clinical databases, development of assessment tools for use in clinical trials and observational studies, as well as analysis of existing cancer control data. These data are used to evaluate patterns and trends in cancer-associated health behaviors and risk factors, health care services, economics, and outcomes, including patient-reported outcomes.